Електронний репозитарій ДВНЗ "УжНУ": Search

Search

Results 1-5 of 5 (Search time: 0.001 seconds).

previous
1
next

Item hits:

Issue Date	Title	Author(s)
2013	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the PAVES Study	Tamás Pintera; Zandra Klippel; Alvydas Cesas; Adina Croitoru; Jochen Decaestecker; Peter Gibbs; Yevhen Hotko; Jacek Jassem; Galina Kurteva; Jan Novotny; Seamus O’Reilly; Tomas Salek; Maureen Reiner; Phuong Khanh Morrow; Mi Rim Choi; Sadie Whittaker; Charles Blanke
2012	Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC)	Alberto F. Sobrero; Marc Peeters; Timothy Jay Price; Yevhen Hotko; Andres Cervantes-Ruiperez; Michel Ducreux; Thierry Andre; Emily Chan; Florian Lordick; Ying Tian; Roger Sidhu
2013	Resultsof a phase III, randomized, double-blind, placebocontrolledtrialofpegfilgrastim (PEG) inpatients (pts) receivingfirst-line FOLFOX or FOLFIRI andbevacizumab (B) forcolorectalcancer (CRC)	Tamas Pinter; Esteban Abella; Alvydas Cesas; Adina Croitoru; Jochen Decaestecker; Peter Gibbs; Yevhen Hotko; Jacek Jassem; Galina Petrova Kurteva; Jan Novotny; Seamus O'Reilly; Tomas Salek; May F. Mo; L. MiRim Choiand Charles Davic Blanke
2015	Analysis of KRAS/NRAS Mutations in a Phase 3 Study of Panitumumab With FOLFIRI Compared With FOLFIRI Alone as Second-Line Treatment for Metastatic Colorectal Cancer	Marc Peeters; Kelly S. Oliner; Timothy Jay Price; Andres Cervantes; Alberto F. Sobrero; Michel Ducreux; Yevhen Hotko; Thierry Andre; Emily Chan; Florian Lordick; Cornelis J. A. Punt; Andrew Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Ying Tian; Andre Scott Jung; Roger Sidhu; Scott D. Patterson
2014-05-20	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).	Marc Peeters; Kelly Smith Oliner; Timothy Jay Price; Andres Cervantes; Alberto F. Sobrero; Michel Ducreux; Yevhen Hotko; Thierry Andre; Emily Chan; Florian Lordick; Cornelis JA Punt; Andrew Strickland; Gregory Wilson; Tudor E Ciuleanu